london trial of olaparib , which is owned by astrazeneca , was led by researchers at the institute of cancer research and the royal marsden hospital .
they found 16 out of 49 men with advanced prostate cancer responded to the drug , also known as lynparza .
it is one of the first of a new class of drugs called parp inhibitors .